GlassScriptPhysician profile
Todd Edward Rambasek
NPI 1093814220
$52,636.86
in general payments reported to CMS, 2019-2025
30 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $2,219 · 2021: $591 · 2022: $16K · 2023: $13K · 2024: $5,973 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $4,930 · Travel and Lodging: $181 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,200.00 |
| Food and Beverage | $4,930.00 |
| Travel and Lodging | $181.35 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35,964.47 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $10,959.85 | 2022-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $2,106.94 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $995.94 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $399.51 | 2020-2025 | Andembry, Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $354.08 | 2020-2025 | Dupixent |
| Optinose US, INC. | $290.91 | 2019-2024 | |
| Genzyme Corporation | $257.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.90 | 2020-2024 | Takhzyro |
| Pfizer INC. | $175.12 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $165.10 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $145.42 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $139.98 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.92 | 2020-2023 | Spiriva Respimat |
| Biocryst US Sales Co., LLC | $69.88 | 2023-2025 | Orladeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $47.31 | 2023-2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $35.50 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.00 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $30.29 | 2025 | Nemluvio |
| Abbvie INC. | $24.56 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.04 | 2025 | Neffy |
| Grifols USA, LLC | $20.67 | 2023 | Xembify |
| Cardinal Health 108 LLC | $20.00 | 2025 | |
| Shire North American Group INC | $16.70 | 2019 | |
| Pharming Healthcare, INC. | $15.99 | 2022 | |
| Horizon Therapeutics Plc | $14.83 | 2021 | |
| Verona Pharma, INC. | $13.76 | 2025 | Ohtuvayre |
| Organon LLC | $7.35 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rambasek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.